Acuitas Therapeutics

Acuitas Therapeutics is a privately held biotechnology company headquartered in Vancouver, British Columbia, Canada. Established in February 2009 as AlCana Technologies and subsequently renamed Acuitas Therapeutics, it specializes in lipid nanoparticle (LNP) delivery systems for nucleic-acid therapeutics. Its technology is intended to encapsulate molecules such as messenger RNA, protect them during administration, and help transport them into target cells. This makes LNPs an enabling component of several emerging therapeutic modalities, including mRNA vaccines, protein-replacement medicines, RNA medicines, and in vivo gene-editing treatments. The company’s origins are connected to the Vancouver lipid-chemistry and drug-delivery research community. Pieter Cullis and colleagues had previously worked on liposomes and nucleic-acid delivery, including through Inex Pharmaceuticals and later Tekmira Pharmaceuticals. Acuitas’s founders built on this research tradition, including the development of ionizable-lipid formulations and the use of polyethylene glycol and other lipid components to improve particle behavior, stability, and cellular delivery. Acuitas has generally operated as a platform and partnership company rather than as a consumer-facing pharmaceutical manufacturer. Its activities include technology development, licensing, collaborative research, and support for partner programs. Acuitas became internationally prominent through its relationship with BioNTech and Pfizer’s BNT162b2 COVID-19 vaccine, later marketed as Comirnaty. The vaccine uses an LNP formulation associated with Acuitas to deliver the mRNA encoding the SARS-CoV-2 spike protein. Health Canada authorized the vaccine in December 2020, bringing broad public attention to the company’s delivery technology and to the importance of LNPs in the commercialization of mRNA medicines. Acuitas has also disclosed or been reported as working with organizations including CureVac, Imperial College London, GC Biopharma, Arbor Biotechnologies, and Bayer. Beyond infectious-disease vaccination, Acuitas describes potential applications in gene editing, protein replacement, oncology, and other nucleic-acid therapies. Its collaboration with Arbor Biotechnologies combines Acuitas delivery systems with CRISPR-based editing approaches for rare liver diseases, while its Bayer partnership concerns in vivo gene-editing products directed to the liver. In 2025, Acuitas LNP technology was reported as part of a personalized CRISPR treatment developed for an infant with severe CPS1 deficiency, an example of how LNP delivery can support individualized genetic medicine. The company remains private, and publicly verifiable information about revenue, valuation, ownership, employee count, and the commercial status of individual partner programs is limited.

Acuitas Therapeutics was established in British Columbia in February 2009 under the name AlCana Technologies by Thomas Madden, Pieter Cullis, and Michael Hope. The company later adopted the Acuitas Therapeutics name and concentrated on delivery systems for nucleic-acid medicines. Its early development was supported in part by Canada’s National Research Council through Industrial Research Assistance Program funding. During its initial years, the company built research capabilities and developed a lipid nanoparticle platform with possible applications in chemotherapy, gene therapy, and genetic vaccination. By 2012, its strategic focus had shifted more specifically toward LNP delivery of messenger RNA. The scientific background of the company reaches back to lipid-delivery research conducted in Vancouver during the 1980s and 1990s. Pieter Cullis was involved in research showing that liposomes could be used to package pharmaceutical compounds. He and colleagues subsequently helped establish Inex Pharmaceuticals, where work included lipid-based drug delivery and cancer-related programs. Cullis and other researchers later developed and patented LNP approaches for delivering genetic material. These approaches included the use of specialized lipids and polyethylene glycol to improve particle properties and promote delivery into cells. Related research and intellectual property also contributed to the formation of other biotechnology ventures, including Protiva Biotherapeutics and the successor organization Tekmira Pharmaceuticals. Acuitas’s development phase included Canadian public research support, including grants reported in 2013 and 2015. In April 2016, it entered a development and option agreement with CureVac to investigate products combining Acuitas LNP technology with CureVac mRNA. The stated work included in vitro and animal testing for a vaccine candidate. Acuitas also participated in efforts related to an mRNA rabies vaccine and maintained collaborations with academic and biopharmaceutical organizations. The company’s profile changed substantially in 2020. Following the emergence of COVID-19, Acuitas began working toward a vaccine program in February of that year. Its LNP formulation became associated with BioNTech and Pfizer’s BNT162b2 vaccine, which uses mRNA to instruct cells to produce the SARS-CoV-2 spike protein. Health Canada authorized the vaccine in December 2020. The success of the program demonstrated the importance of LNP delivery to the practical deployment of mRNA vaccines and made Acuitas one of the more visible specialist companies in the field. Acuitas also worked with CureVac and Imperial College London on vaccine-related efforts. After the initial COVID-19 vaccine period, Acuitas broadened its publicly described partnerships and applications. In 2022, it entered a long-term partnership with Science World, agreed to work with GC Biopharma on LNP-mRNA vaccines and therapeutics, donated to the Brain Tumour Foundation of Canada to establish the Frazer Anderson Pediatric Research Grant, and partnered with Arbor Biotechnologies on CRISPR-based approaches for rare liver diseases. In 2023, Bayer announced a partnership with Acuitas focused on using LNPs to deliver in vivo gene-editing products to the liver. In 2025, reports identified Acuitas LNPs as part of a personalized CRISPR treatment for an infant with severe CPS1 deficiency. The therapy was developed by researchers and organizations including Children’s Hospital of Philadelphia, the University of Pennsylvania, and the Innovative Genomics Institute, with RNA-related manufacturing contributions from Aldevron and Integrated DNA Technologies. The case illustrated the potential of combining patient-specific genetic design with targeted nucleic-acid delivery, although it represented an individualized medical intervention rather than a conventional mass-market product. Acuitas remains a private company. It participates in the Canadian biotechnology ecosystem through organizations such as BIOTECanada and Life Sciences British Columbia and has supported the Vancouver Student Biotechnology Network. The company does not publicly disclose a complete customer list, detailed financial statements, valuation, or the full development status of all partnered programs. Claims that Canadian Prime Minister Justin Trudeau or the Trudeau Foundation owned a large stake in Acuitas were publicly denied by the Prime Minister’s Office, Thomas Madden, and Pieter Cullis.

• 2025

  Personalized CRISPR case uses Acuitas LNPs

  [1]Acuitas Therapeuticsen.wikipedia.org

  A reported bespoke treatment for an infant with CPS1 deficiency uses Acuitas LNPs as part of a patient-specific CRISPR intervention.

• 2023

  Bayer gene-editing partnership

  [1]Acuitas Therapeuticsen.wikipedia.org

  Bayer announces a collaboration with Acuitas to use LNPs for in vivo gene-editing delivery to the liver.

• 2022

  Expansion into gene-editing and public science partnerships

  [1]Acuitas Therapeuticsen.wikipedia.org

  Acuitas announces or completes partnerships involving Science World, GC Biopharma, and Arbor Biotechnologies, broadening its activities beyond vaccine delivery.

• 2020

  LNP technology enters a major COVID-19 vaccine program

  [1]Acuitas Therapeuticsen.wikipedia.org

  Acuitas’s delivery system becomes associated with Pfizer and BioNTech’s BNT162b2 mRNA vaccine program.

• 2020

  Health Canada authorizes BNT162b2

  [1]Acuitas Therapeuticsen.wikipedia.org

  Health Canada authorizes the Pfizer–BioNTech COVID-19 vaccine, whose delivery formulation uses Acuitas-associated LNP technology.

• 2016

  Development agreement with CureVac

  [1]Acuitas Therapeuticsen.wikipedia.org

  Acuitas and CureVac agree to develop an mRNA product using Acuitas’s LNP technology for preclinical testing.

• 2013

  NRC IRAP research support

  [1]Acuitas Therapeuticsen.wikipedia.org

  The National Research Council of Canada provides reported research funding to support the company’s LNP development work.

• 2012

  Focus shifts to mRNA delivery

  [1]Acuitas Therapeuticsen.wikipedia.org

  The company adopts a more focused strategy centered on lipid nanoparticle delivery of messenger RNA.

• 2009

  AlCana Technologies is established

  [1]Acuitas Therapeuticsen.wikipedia.org

  Thomas Madden, Pieter Cullis, and Michael Hope establish AlCana Technologies in British Columbia to develop nucleic-acid delivery technologies.

A specialist enabling-technology provider for mRNA medicines, vaccines, RNA therapeutics, and in vivo gene editing.

• Drug-delivery platform

  Acuitas LNP delivery technology

  Acuitas’s principal technology platform uses lipid nanoparticles to package and deliver nucleic-acid payloads, including mRNA. The particles are designed to protect the payload, support administration, and facilitate uptake into target cells. The platform is licensed or applied through collaborative programs rather than sold as a conventional branded medicine, and has been associated with vaccines, protein-replacement concepts, RNA therapeutics, and in vivo gene-editing research.

• Vaccine-enabling technology

  mRNA vaccine delivery applications

  The company’s LNP systems have been used in mRNA vaccine development, most prominently in the Pfizer–BioNTech COVID-19 vaccine program. In this setting, the nanoparticles deliver mRNA encoding an antigen so that cells can produce the relevant protein and stimulate an immune response. Acuitas has also been connected with exploratory vaccine work involving diseases such as rabies and with collaborations involving other vaccine developers.

• Genetic-medicine platform

  In vivo gene-editing delivery

  Acuitas applies its LNP technology to the delivery of gene-editing components, including programs aimed at the liver. Partnerships with Arbor Biotechnologies and Bayer have focused on combining LNP delivery with CRISPR or other in vivo editing approaches. The technology has also been reported in a highly individualized CRISPR treatment for CPS1 deficiency, demonstrating a potential role in bespoke genetic medicine.

• 2022Science World partnership

  Canada

  Acuitas entered a long-term partnership with Science World in Vancouver to support public science education and engagement.

  Outcome. The partnership added a public-education and community-engagement dimension to Acuitas’s biotechnology activities.

  Source
• 2022Brain Tumour Foundation pediatric research support

  Canada

  Acuitas donated $25,000 to the Brain Tumour Foundation of Canada to establish the Frazer Anderson Pediatric Research Grant.

  Outcome. The donation supported pediatric brain-tumor research through a named grant program.

  Source

• 2023

  Extend LNP work into in vivo gene editingStrategy

  Background

  Interest in genetic medicines expanded from mRNA vaccination toward direct editing of disease-related genes.

  Action taken

  Acuitas partnered with Bayer on delivery of in vivo gene-editing products to the liver.

  Aftermath

  The agreement broadened the company’s partnership portfolio beyond infectious-disease vaccines.

  Source

• 2020

  Support the Pfizer–BioNTech COVID-19 vaccine programProduct launch

  Background

  The COVID-19 pandemic created an urgent need for scalable delivery of mRNA vaccines.

  Action taken

  Acuitas supported the vaccine program with an LNP formulation for delivery of BioNTech’s mRNA.

  Aftermath

  The vaccine’s authorization made Acuitas’s delivery technology internationally prominent.

  Source

• 2012

  Concentrate the platform on mRNA deliveryStrategy

  Background

  After several years of work on broader applications for lipid nanoparticles, Acuitas determined that messenger RNA delivery offered a focused strategic opportunity.

  Action taken

  The company prioritized LNP development for mRNA medicines and vaccines.

  Aftermath

  This focus positioned Acuitas to participate in later mRNA vaccine and genetic-medicine programs.

  Source

1. 1Acuitas Therapeuticsen.wikipedia.org
2. 2Acuitas Therapeutics official websiteacuitastx.com